We’ve compiled lists of the five most-read biological chemistry articles across ACS journals in September 2019, including research, reviews, perspectives, and editorial pieces.

There are lots of different ways to look at the reach of an article. You can look at citations, Altmetric Attention Scores, awards, and more. One way to consider the influence of an article is just by looking at how many people chose to read it. To that end, we’ve compiled lists of the five most-read chemistry articles that appeared in each ACS Publications journal in September 2019, including research, reviews, perspectives, and editorial pieces. These lists were not chosen by the journal’s editors and should not be taken as a “best of” list, but as another perspective on where the chemistry community allocated their attention.

Get free monthly updates on the most-read research in your field.

Read more of September’s most-read articles.

***

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
DOI: 10.1021/acs.jmedchem.9b00794

A Comparative Assessment Study of Known Small-Molecule Keap1−Nrf2 Protein–Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity
DOI: 10.1021/acs.jmedchem.9b00723

Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma
DOI: 10.1021/acs.jmedchem.9b00555

Bicyclic Boronate VNRX-5133 Inhibits Metallo- and Serine-β-Lactamases
Open Access Through ACS AuthorChoice
DOI: 10.1021/acs.jmedchem.9b00911

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
DOI: 10.1021/acs.jmedchem.9b00687

[/expand]

Want the latest stories delivered to your inbox each month?